Brauchen wir die Grippemittel Tamiflu und Relenza?
2195-8831
Abstract
Lately, several press releases as well as a parliamentary inquiry questioned the effectiveness of the neuraminidase inhibitors (NAI, oseltamivir and zanamivir) in concerns of therapy of influenza. However, in combination with the unfortunate data communication by the pharma industry after the latest analysis by the Cochrane Collaboration an opinion evolved and was spread supporting the view that the neuraminidase inhibitors are in fact not effective at all.All three scientific expert societies (GfV, DVV and PEG) are considering this point illegitimate and also dangerous simplification. On the one hand, the recent analysis by the Cochrane Collaboration confirms a significant reduction in time to first alleviation of symptoms in children (oseltamivir) and adults (oseltamivir and zanamivir). On the other hand, due to basic methodical specifications, the analyses of the Cochrane Collaboration does not include any results of observational studies revealing that especially with patients at risk, indeed, there was a positive effect of neuraminidase inhibitors. As long as there is no availability of any better antiviral substances against influenza viruses, the possibility of applying the existing neuraminidase inhibitors must be considered carefully for each respective situation and used for the good of the patients as well.